Most cancer drugs introduced since 2004 provide low added value compared to previously approved medications, but have much higher prices, according to a French study presented at the congress of the European Society for Medical Oncology [more]
Should regulators insist on robust evidence that a new drug shows clear benefit to patients as a condition of approval, or are demands for such levels of certainty unrealistic, or even unethical? Marc Beishon reports [more]
Does robotic surgery offer superior outcomes? Yes and no – or better: yes and maybe – answers a study published earlier this month in The Lancet Oncology: their clinical benefit is still uncertain, but robots [more]
The head of Medical Oncology at Ioannina University Hospital not only oversees ESMO’s prolific output of clinical guidelines, but also helps ensure that they can be sustainably delivered in his own country, where hospital budgets [more]